Open AccessT087: Brentuximab vedotin (Bv) Demonstrates Superior Event‐Free Survival in Pediatric High‐Risk Hodgkin Lymphoma
Author(s) -
Castellino Sharon M.,
Pei Qinglin,
Parsons Susan K.,
Hodgson David,
McCarten Kathleen,
Horton Terzah,
Cho Steve,
Wu Yue,
Punnett Angela,
Dave Hema,
Henderson Tara O.,
Hoppe Bradford S.,
Charpentier AnnMarie,
Keller Frank G.,
Kelly Kara M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890916.12776.84
Subject(s) - brentuximab vedotin , medicine , vincristine , etoposide , hazard ratio , prednisone , oncology , regimen , lymphoma , gastroenterology , cd30 , surgery , cyclophosphamide , chemotherapy , confidence interval